RT Conference Proceedings
T1 Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
A1 Casarrubios, M.
A1 Cruz-Bermudez, A.
A1 Sierra-Rodero, B.
A1 Nadal, E.
A1 Insa-Molla, M. A.
A1 Garcia-Campelo, M. R.
A1 Garcia-Benito, C.
A1 Domine-Gomez, M.
A1 Majem-Tarruella, M.
A1 Rodriguez-Abreu, D.
A1 Martinez, A.
A1 De-Castro-Carpeno, J.
A1 Cobo-Dols, M.
A1 Lopez-Vivanco, G.
A1 Vinolas-Segarra, N.
A1 Barneto-Aranda, I. C.
A1 Viteri, S.
A1 Massuti-Sureda, B.
A1 Provencio-Pulla, M.
K1 Tumor Microenvironment
K1 Carcinoma, Non-Small-Cell Lung
K1 Gene Expression Profiling
AB Background: Neoadjuvant chemoimmunotherapy (CI) for NSCLC is a promising strategy that yields high rates of complete pathological responses (CPR) that are associated with long-term survival. We analyzed the tumor microenvironment by using gene expression profiling in patients from NADIM trial to identify biomarkers predicting CPR. Methods: RNAs extracted from whole sections of pre-treatment tumors of 14 patients enrolled in NADIM trial (NCT03081689) were sequenced using the Oncomine Immune Response Research Assay panel. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and Gene Set Enrichment Analysis (GSEA). CIBERSORTx was used to estimate the proportions of immune cells subtypes. Results were correlated with pathological response groups: complete (CPR, n¼9) and non-complete (non-CPR, n¼5) responders.
PB Elsevier
SN 0923-7534
YR 2022
FD 2022-04-02
LK http://hdl.handle.net/10668/21894
UL http://hdl.handle.net/10668/21894
LA en
NO Casarrubios, M., Cruz-Bermudez, A., Sierra-Rodero, B., Nadal, E., Molla, M. I., Campelo, G., et al. Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy. Annals Of Oncology, 33, S105. https://doi.org/10.1016/j.annonc.2022.02.189
DS RISalud
RD Apr 11, 2025